Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)

NCT07688980 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

COMBINATION_PRODUCT: Anifrolumab: SC formulation via AI
COMBINATION_PRODUCT: Anifrolumab: IV formulation
COMBINATION_PRODUCT: Anifrolumab: SC formulation via aPFS

Sponsor

AstraZeneca

Collaborators

[object Object]